Chimerix, Inc. - Common Stock (CMRX)
Frequently Asked Questions About Chimerix, Inc. - Common Stock (CMRX)
Are there any partnerships or collaborations involving Chimerix?
Chimerix has engaged in partnerships and collaborations with various healthcare organizations and academic institutions to further enhance its research capabilities and expand the potential applications of its antiviral products.
How can I invest in Chimerix?
Investors can purchase shares of Chimerix through brokerage accounts that allow trading on the Nasdaq stock exchange, and it is advisable to research and understand the biopharmaceutical sector before investing.
How does Chimerix approach drug development?
Chimerix employs a strategic approach to drug development that emphasizes scientific rigor, patient-centered research, and collaboration with healthcare providers to ensure that their therapies meet the needs of patients and the medical community.
How does Chimerix evaluate the safety of its products?
Chimerix evaluates the safety of its products through rigorous clinical trials regulated by the FDA and other regulatory authorities, ensuring that they meet strict safety and efficacy standards before market approval.
Is Chimerix a publicly traded company?
Yes, Chimerix, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol CMRX. This allows investors to buy and sell shares of the company.
What are some recent developments from Chimerix?
Recent developments from Chimerix include advancements in the clinical trials for brincidofovir and partnerships aimed at expanding the use of their therapies in addressing various viral infections in vulnerable patient populations.
What diseases does Chimerix focus on treating?
Chimerix primarily focuses on treating viral infections associated with immunocompromised patients, including cytomegalovirus (CMV), adenovirus, and potentially other viral pathogens, thereby enhancing patient care in oncology and transplant settings.
What does Chimerix, Inc. do?
Chimerix, Inc. is a biopharmaceutical company focused on developing antiviral therapies, primarily for the treatment of serious infections in immunocompromised patients. The company’s lead product candidate is brincidofovir, an antiviral agent designed to treat diseases such as cytomegalovirus (CMV), adenovirus, and other viral infections.
What financial resources does Chimerix have?
Chimerix has raised capital through public offerings and partnerships, allowing the company to fund ongoing research, clinical trials, and operational needs to support its mission of developing antiviral therapies.
What is brincidofovir?
Brincidofovir is Chimerix’s lead investigational antiviral drug designed to treat serious viral infections, including those caused by cytomegalovirus (CMV) in patients who are immunocompromised. It is an oral prodrug of cidofovir intended to improve efficacy and reduce nephrotoxicity.
What is the company's mission?
Chimerix's mission is to discover, develop, and commercialize innovative antiviral solutions to improve healthcare outcomes for patients suffering from serious viral infections, particularly in immunocompromised populations.
What is the current status of Chimerix's product candidates?
As of the latest available information, Chimerix is actively pursuing clinical trials for brincidofovir and is also exploring opportunities for advancing other antiviral compounds in its pipeline, addressing various viral infections.
What is the FDA's role in Chimerix's drug development?
The FDA plays a critical role in Chimerix's drug development process by reviewing clinical trial data, approving investigational new drugs (INDs), and ultimately evaluating the safety and effectiveness of the company's products for market release.
What is the significance of the company’s name, Chimerix?
The name Chimerix is derived from 'chimera,' which in biology denotes an organism or tissue made up of multiple genetic sources. This reflects the company's mission to develop innovative and versatile therapeutic solutions to tackle complex viral infections.
What types of clinical trials does Chimerix conduct?
Chimerix conducts Phase 1, Phase 2, and Phase 3 clinical trials aimed at assessing the safety, efficacy, and dosage of its antiviral therapies to ensure they meet regulatory and patient needs before potential commercialization.
When was Chimerix founded?
Chimerix was founded in 2000 and has since been dedicated to advancing antiviral therapies to address unmet medical needs, especially for patients with weakened immune systems.
Where is Chimerix located?
Chimerix is headquartered in Durham, North Carolina, a region known for its vibrant biotech ecosystem, which supports the company’s research and clinical development efforts.
Who are the founders of Chimerix?
Chimerix was co-founded by Dr. Michael B. B. Deisenhofer and Dr. Judith A. Kay, aiming to leverage research and innovation in antiviral drug development to improve patient outcomes.
Who is the CEO of Chimerix?
The CEO of Chimerix is Dr. Michael H. Vassallo, who has extensive experience in the pharmaceutical and biotechnology industries, focusing on advancing the company's strategic goals and clinical programs.
What is the current price of Chimerix, Inc. - Common Stock?
The current price of Chimerix, Inc. - Common Stock is 8.520
When was Chimerix, Inc. - Common Stock last traded?
The last trade of Chimerix, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Chimerix, Inc. - Common Stock?
The market capitalization of Chimerix, Inc. - Common Stock is 785.54M
How many shares of Chimerix, Inc. - Common Stock are outstanding?
Chimerix, Inc. - Common Stock has 92.20M shares outstanding.